Skip to main content

Table 4 Comparison of administered treatments in patients with single and co-ingestant exposures to methadone

From: Clinical characteristics and time trends of hospitalized methadone exposures in the United States based on the Toxicology Investigators Consortium (ToxIC) case registry: 2010–2017

Variable Total Single exposure of methadone (n = 354) Co exposure of Methadone with other drugs (n = 619)
Naloxone Yes 442 (45.4%) 125 (35.3%) 317 (51.2%)
No 531 (54.6%) 232 (65.5%) 299 (48.3%)
N-acetylcysteine Yes 40 (4.2%) 27 (7.6%) 13 (2.1%)
No 933 (95.8%) 330 (93.2%) 603 (97.4%)
Flumazenil Yes 22 (2.3%) 9 (2.5%) 13 (2.1%)
No 951 (97.7%) 348 (98.3%) 603 (97.4%)
Sodium bicarbonate Yes 21 (2.2%) 13 (2.77%) 8 (1.29%)
No 952 (97.8%) 344 (97.2%) 608 (98.2%)
Vasopressors Yes 34 (3.5%) 26 (7.34%) 8 (1.29%)
No 939 (96.5%) 331 (93.5%) 608 (98.2%)
Anticonvulsants Yes 13 (1.4%) 8 (2.3%) 5 (0.81%)
No 960 (98.6%) 349 (98.6%) 611 (98.7%)
Antipsychotics Yes 25 (2.6%) 10 (2.8%) 15 (2.42%)
No 948 (97.4%) 347 (98.2%) 601 (97.1%)
Benzodiazepine Yes 119 (12.3%) 66 (18.6%) 53 (8.56%)
No 854 (87.7%) 291 (81.5%) 563 (90.9%)
Opioids Yes 38 (4.0%) 27 (8.22%) 11 (1.77%)
No 935 (96.0%) 330 (93.2%) 605 (97.7%)